论文部分内容阅读
埃博拉病毒(EBOV)是一种高度致命的烈性病毒,能够引起人类和灵长类动物发生埃博拉出血热,死亡率高达50%以上。2013年底以来,EBOV在西非蔓延,由于缺乏有效的治疗,已经夺去了数千人的生命。目前,在研的防治埃博拉病毒的药物主要包括疫苗、小分子药物和抗体等,其中小分子药物以其生产迅速、产量大、性质稳定的优点而备受关注。简述抗EBOV小分子化合物的最新研究进展。
Ebola virus (EBOV) is a highly virulent and virulent virus that causes human and primate Ebola hemorrhagic fever with a mortality rate of more than 50%. Since the end of 2013, EBOV has spread in West Africa and has claimed the lives of thousands of people due to the lack of effective treatment. At present, the drugs for preventing and treating Ebola under study mainly include vaccines, small molecule drugs and antibodies, among which small molecule drugs have drawn much attention for their rapid production, large yield and stable properties. The latest research progress on anti-EBOV small molecule compounds is briefly reviewed.